Most grade II and grade III gliomas, as well as the secondary glioblastomas that arise from these tumors, possess point mutations that affect the substrate binding site of isocitrate dehydrogenase. These mutations are essentially unique to gliomas, seem to represent an early step in gliomagenesis, and confer a favorable prognosis.
This is a preview of subscription content, log in via an institution to check access.
References
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
Ohgaki, H. & Kleihues, P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170, 1445–1453 (2007).
Schiff, D., Brown, P. D. & Giannini, C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69, 1366–1373 (2007).
Thompson, C. B. Metabolic enzymes as oncogenes or tumor suppressors. N. Engl. J. Med. 360, 813–815 (2009).
Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
Balss, J. et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116, 597–602 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Schiff, D., Purow, B. Isocitrate dehydrogenase mutations in low-grade gliomas. Nat Rev Neurol 5, 303–304 (2009). https://doi.org/10.1038/nrneurol.2009.57
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2009.57
- Springer Nature Limited
This article is cited by
-
Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples
BMC Biochemistry (2010)